Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.47 |
| ▸ | VEGFA | P15692 | 2/20 | 0.46 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565270 | 0.97 | EGLN1 (0.47) | EGLN1ALDH1A1LMNAPDE2APDE3B | |
| SCHEMBL6566238 | 0.97 | EGLN1 (0.47) | EGLN1ALDH1A1LMNAPDE2APDE3B | |
| SCHEMBL6567272 | 0.97 | EGLN1 (0.47) | EGLN1ALDH1A1LMNAPDE2APDE3B | |
| SCHEMBL1509148 | 0.95 | EGLN1 (0.50) | EGLN1PDE2APDE3BPDE3AFTO | |
| SCHEMBL6565277 | 0.91 | EGLN1 (0.47) | EGLN1PDE2APDE3BPDE3AFTO | |
| SCHEMBL6567256 | 0.91 | EGLN1 (0.50) | EGLN1ALDH1A1LMNAFTOEGLN3 | |
| SCHEMBL6566125 | 0.91 | EGLN1 (0.52) | EGLN1FTOEGLN3VEGFAFLT1 | |
| SCHEMBL8625366 | 0.90 | EGLN1 (0.44) | EGLN1ALDH1A1LMNAEGLN3 | |
| SCHEMBL8633329 | 0.89 | EGLN1 (0.54) | EGLN1FTO | |
| SCHEMBL8628234 | 0.87 | EGLN1 (0.45) | EGLN1PDE2APDE3BPDE3AFTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | claimed |
| CN-101664408-B | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2013-05-01 | — | — | CN | claimed |
| EP-1463823-B1 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210114987-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20210107878-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. | 2021-04-15 | — | — | US | disclosed |
| WO-2003049686-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-5726305-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-10 | — | — | US | disclosed |
| US-5719164-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | disclosed |
| US-5620995-A | Substituted heterocyclic carboxyamides, their preparation and their use as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | disclosed |
| EP-0765871-A1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
| EP-0661269-B1 | Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments | HOECHST AG (DE) | 1997-03-26 | — | — | EP | disclosed |
| CN-1126203-A | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals | HOECHST AG (DE) | 1996-07-10 | — | — | CN | disclosed |
| EP-0661269-A1 | Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885ALDH1A1 503/4885LMNA 3540/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | EGLN1 863/4885ALDH1A1 3748/4885LMNA 3860/4885 |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN1 24/4885ALDH1A1 847/4885LMNA 3878/4885 |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN1 21/4885ALDH1A1 869/4885LMNA 3839/4885 |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885ALDH1A1 503/4885LMNA 3540/4885 |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | EGLN1 24/4885ALDH1A1 847/4885LMNA 3878/4885 |
| US-20210114987-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | EGLN1 24/4885ALDH1A1 847/4885LMNA 3878/4885 |
| US-20210107878-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | EGLN1 21/4885ALDH1A1 869/4885LMNA 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.